Orchestra BioMed Holdings Overview
Latest ROE for Orchestra BioMed Holdings: -201.51% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-201.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for OBIO is -201.51%. That is below the sector sector average of 11.64%. Investors often review this figure alongside Orchestra BioMed Holdings's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, OBIO currently prints -201.51% for ROE, while the sector average sits near 11.64%. That is roughly 1831.7% below the sector mean. Large gaps often invite a closer look at Orchestra BioMed Holdings's growth, margins, and balance sheet.
Return on Equity shows how effectively Orchestra BioMed Holdings converts resources into returns. At -201.51%, OBIO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting OBIO's ROE (-201.51%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
